This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

Lysogene Valuation

Is LYS undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of LYS when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate LYS's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate LYS's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LYS?

Key metric: As LYS is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for LYS. This is calculated by dividing LYS's market cap by their current revenue.
What is LYS's PS Ratio?
PS Ratio	0.4x
Sales	€12.77m
Market Cap	€4.95m

LYS key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	0.8x
Enterprise Value/EBITDA	-1.4x
PEG Ratio	n/a

Price to Sales Ratio vs Peers

How does LYS's PS Ratio compare to its peers?

The above table shows the PS ratio for LYS vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PS	Estimated Growth	Market Cap
Peer Average	2.5x
ALVET TheraVet	0.4x	n/a	€380.1k
ALMDP Medesis Pharma	6.9x	n/a	€2.1m
ALINT IntegraGen	0.2x	n/a	€3.1m
ALPAT Plant Advanced Technologies	n/a	18.8%	€13.7m
LYS Lysogene	0.4x	n/a	€4.9m

Price-To-Sales vs Peers: LYS is good value based on its Price-To-Sales Ratio (0.4x) compared to the peer average (1.8x).

Price to Sales Ratio vs Industry

How does LYS's PS Ratio compare vs other companies in the FR Biotechs Industry?

7 Companies	Price / Sales	Estimated Growth	Market Cap
Industry Avg.	4.4x	32.4%
LYS Lysogene	0.4x	n/a	US$5.42m
ALGEN genOway Société anonyme	1.1x	n/a	US$33.35m
ALINT IntegraGen	0.2x	n/a	US$3.27m

7 Companies		Estimated Growth	Market Cap
Industry Avg.	4.4x	5.0%
LYS Lysogene	0.4x	n/a	US$5.42m

No more companies

Price-To-Sales vs Industry: LYS is good value based on its Price-To-Sales Ratio (0.4x) compared to the French Biotechs industry average (4.6x)

Price to Sales Ratio vs Fair Ratio

What is LYS's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LYS PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio	0.4x
Fair PS Ratio	n/a

Price-To-Sales vs Fair Ratio: Insufficient data to calculate LYS's Price-To-Sales Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Sanofi

€118.3b

A healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally.

SAN

€94.40

-1.4%

11.3%

Eurofins Scientific

€8.7b

Provides various analytical testing and laboratory services worldwide.

ERF

€46.17

1.5%

-12.0%

Theranexus Société Anonyme

€3.9m

A biopharmaceutical company, engages in the development of drug candidates for the treatment of central nervous system disorders.

ALTHX

€0.50

-0.4%

-56.6%